Final Analysis Of The Atlantis Cabozantinib Comparison

Final analysis of the ATLANTIS cabozantinib comparison

European Association of Urology

Final results from ATLANTIS cabozantinib arm for urothelial carcinoma

ATLANTIS rules out cabozantinib as a maintenance option for mUC | Robert Jones

Medicine Matters oncology

Results of a Trial Comparing Cabozantinib and Sunitinib in mRCC

Targeted Oncology

Cabozantinib–nivolumab and ipilimumab combinations show potential for GU cancers | Andrea Apolo

Medicine Matters oncology

CARINA: cabozantinib post first-line immune-oncology CPI-containing combination in aRCC

Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma

AJE Video Bytes

Cabozantinib most effective treatment for metastatic papillary kidney cancer

#ESMO22 Highlights on cabozantinib with nivo and ipi for intermediate/poor risk adv. RCC: COSMIC-313

European Society for Medical Oncology (ESMO)

COSMIC-021: Cabozantinib + atezolizumab gives clinical activity in inoperable metastatic UC

CABOSUN Trial: Cabozantinib vs Sunitinib for Renal Cell Carcinoma

Targeted Oncology

Phase II trial of cabozantinib for patients with HCC previously treated with IO

Cabozantinib demonstrates disease control in advanced adrenocortical carcinoma

Cabozantinib for advanced renal cell carcinoma: the METEOR and CABOSUN trials

Kidney Cancer Trial (The Radical Study)

Doctor Grew Explains Cancer

Dr. Apolo on Side Effects of Cabozantinib Plus Immunotherapy Agents in Bladder Cancer

Dr. Ezra Cohen Discusses the Cabozantinib EXAM Trial

Advanced HCC: CELESTIAL Trial

Targeted Oncology

The Rationale for Using Cabozantinib

Targeted Oncology

Cabozantinib after checkpoint inhibitors demonstrates preliminary efficacy in advanced RCC